Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma
Jatin J. Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, D. Tomaras, Gabriel Tremblay, Olivier Casasnovas, Marie Maerevoet, Josée M. Zijlstra, George Follows, Joost S.P. Vermaat, Nagesh Kalakonda, André Goy, Sylvain Choquet, Éric Van Den Neste, Brian T. Hill, Catherine Thiéblemont, Federica Cavallo, Fátima De la Cruz, John Kuruvilla, Nada Hamad, Réda Bouabdallah, Ulrich Jäger, Paolo F. Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan‐Manuel Sancho, Michael Schuster, Miklós Egyed, Fritz Offner, T. Vasilakopoulos, Priyanka Samal, Ágnes Nagy, Matthew Ku, Miguel Canales
Abstract
In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.